

# Nectar Lifesciences Ltd


## Q4FY11 Result Summary

Rs mn	Q4FY11	Q3FY11	Q4FY10	q-o-q (%)	y-o-y (%)
Net Sales	3414	3228	2437	6	40
Other Income	134	1	128	10177	5
Raw Material Cost	2376	2201	1642	8	45
Employees cost	107	109	79	-2	35
Other expenses	274	234	219	17	25
EBITDA	790	685	625	15	27
EBITDA margin	23	21	26	190bps	-250bps
Depreciation	112	116	95	-4	18
EBIT	679	568	530	19	28
Interest and finance charges	348	157	197	122	77
PBT	330	412	333	-20	-1
Tax	12	109	67	-89	-82
PAT	318	302	266	5	20
PAT Margin (%)	9	9	11	-10bps	-160bps
No of equity shares (Mn)	224	224	224		
EPS (Rs)	1.4	1	1.2	40.0	16.7


The company registered strong top line growth of ~40% y-o-y in Q4FY11 on the back of better performance of API business during the quarter. The company has received approvals from Japan and South Africa for two of its API molecules and has filed four DMFs in Q4FY11, three for the US and one for Europe.

Despite growth in top line, operating margins dropped by ~250 basis points because of increase in material cost by ~45% and employee cost by 35% in Q4FY11 as compared to the corresponding quarter of the previous year.


### Revenue and EBITDA margins




### PAT and PAT margins



### Share price movement



### Shareholding pattern



### Additional Disclosure

This report has been sponsored by NSE - Investor Protection Fund Trust (NSEIPFT).

### Disclaimer

This report is based on data publicly available or from sources considered reliable. CRISIL Ltd. (CRISIL) does not represent that it is accurate or complete and hence, it should not be relied upon as such. The data / report is subject to change without any prior notice. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The subscriber / user assume the entire risk of any use made of this data / report. CRISIL especially states that, it has no financial liability whatsoever, to the subscribers / users of this report. This report is for the personal information only of the authorised recipient in India only. This report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person – especially outside India or published or copied in whole or in part, for any purpose.

CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of this report. For information please contact 'Client Servicing' at +91-22-33423561, or via e-mail: clientservicing@crisil.com.